Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.62, $0.02 better than the analyst estimate of $0.60. Revenue for the quarter came in at $100.45 million versus the consensus estimate of $111.53 million.

GUIDANCE:

Supernus Pharma sees FY2020 revenue of $360-390 million, versus the consensus of $407.7 million.

• Operating earnings to range from $70 million to $100 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.